Repository logo
 
Publication

Rivaroxabananddabigatraninpatientsundergoing catheter ablation of atrial fibrillation

2014Journal article Open access
Simple item page
dc.contributor.authorMorais, João
dc.contributor.authorProvidência, Rui
dc.contributor.authorBoveda, Serge
dc.contributor.authorJourda, François
dc.contributor.authorHireche, Hassiba
dc.contributor.authorCombes, Stéphane
dc.contributor.authorCombes, Nicolas
dc.contributor.authorMarijon, Eloi
dc.contributor.authorAlbenque, Jean-Paul
dc.date.accessioned2016-06-16T09:02:29Z
dc.date.available2016-06-16T09:02:29Z
dc.date.issued2014
dc.description.abstractAims: The recent availability of the novel oral anticoagulants (NOACs) may have led to a change in the anticoagulation regimens of patients referred to catheter ablation of atrial fibrillation (AF). Preliminary data exist concerning dabigatran, but information regarding the safety and efficacy of rivaroxaban in this setting is currently scarce. Methods: and results Of the 556 consecutive eligible patients (age 61.0 ± 9.6; 74.6% men; 61.2% paroxysmal AF) undergoing AF catheter ablation in our centre (October 2012 to September 2013) and enroled in a systematic standardized 30-day follow-up period: 192 patients were under vitamin K antagonists (VKAs), 188 under rivaroxaban, and 176 under dabigatran. Peri-procedural mortality and significant systemic or pulmonary thromboembolism (efficacy outcome), as well as bleeding events (safety outcome) during the 30 days following the ablation were evaluated according to anticoagulation regimen. During a 12-month time interval, the use of the NOACs in this population rose from <10 to 70%. Overall, the rate of events was low with no significant differences regarding: thrombo-embolic events in 1.3% (VKA 2.1%; rivaroxaban 1.1%; dabigatran 0.6%; P = 0.410); major bleeding in 2.3% (VKA 4.2%; rivaroxaban 1.6%; dabigatran 1.1%; P = 0.112), and minor bleeding 1.4% (VKA 2.1%; rivaroxaban 1.6%; dabigatran 0.6%; P = 0.464). No fatal events were observed. Conclusion: The use of the NOAC in patients undergoing catheter ablation of AF has rapidly evolved (seven-fold) over 1 year. These preliminary data suggest that rivaroxaban and dabigatran in the setting of catheter ablation of AF are efficient and safe, compared with the traditional VKA.pt_PT
dc.identifier.doi10.1093/europace/euu007pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.26/14065
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectAtrial fibrillationpt_PT
dc.subjectRivaroxabanpt_PT
dc.subjectDabigatranpt_PT
dc.subjectVitamin K antagonistspt_PT
dc.subjectFluindionept_PT
dc.subjectStrokept_PT
dc.subjectCryoablationpt_PT
dc.subjectThromboembolismpt_PT
dc.subjectBleedingpt_PT
dc.subjectArrhythmiapt_PT
dc.titleRivaroxabananddabigatraninpatientsundergoing catheter ablation of atrial fibrillationpt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage8pt_PT
oaire.citation.startPage1pt_PT
oaire.citation.titleEuropace Advancept_PT
oaire.citation.volume16 (8)pt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Rivaroxabananddabigatraninpatientsundergoing catheter ablation of atrial fibrillation - João Morais.pdf
Size:
180.26 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

CI - CHL - Cardiologia - Artigos